SG11201708158PA - Composition for suppressing muscular fatty change - Google Patents
Composition for suppressing muscular fatty changeInfo
- Publication number
- SG11201708158PA SG11201708158PA SG11201708158PA SG11201708158PA SG11201708158PA SG 11201708158P A SG11201708158P A SG 11201708158PA SG 11201708158P A SG11201708158P A SG 11201708158PA SG 11201708158P A SG11201708158P A SG 11201708158PA SG 11201708158P A SG11201708158P A SG 11201708158PA
- Authority
- SG
- Singapore
- Prior art keywords
- composition
- fatty change
- suppressing muscular
- muscular
- suppressing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015090580 | 2015-04-27 | ||
| PCT/JP2016/062700 WO2016175136A1 (ja) | 2015-04-27 | 2016-04-22 | 筋脂肪化抑制用組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201708158PA true SG11201708158PA (en) | 2017-11-29 |
Family
ID=57198430
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201708158PA SG11201708158PA (en) | 2015-04-27 | 2016-04-22 | Composition for suppressing muscular fatty change |
| SG10201909412R SG10201909412RA (en) | 2015-04-27 | 2016-04-22 | Composition for suppressing muscular fatty change |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201909412R SG10201909412RA (en) | 2015-04-27 | 2016-04-22 | Composition for suppressing muscular fatty change |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180104269A1 (ja) |
| JP (1) | JP7013238B2 (ja) |
| CN (1) | CN107530320A (ja) |
| CA (1) | CA2982645C (ja) |
| HK (1) | HK1246182A1 (ja) |
| SG (2) | SG11201708158PA (ja) |
| TW (1) | TW201713330A (ja) |
| WO (1) | WO2016175136A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018087175A (ja) * | 2016-11-30 | 2018-06-07 | 花王株式会社 | 筋萎縮抑制剤 |
| US20190388387A1 (en) * | 2017-03-10 | 2019-12-26 | Suntory Holdings Limited | Composition for inhibiting myofibrosis |
| WO2019208627A1 (ja) * | 2018-04-27 | 2019-10-31 | サントリーホールディングス株式会社 | 筋肉量減少抑制用、筋力低下抑制用、筋肉量増加用又は筋力増加用の組成物 |
| EP4066897A4 (en) * | 2019-11-27 | 2023-12-27 | Suntory Holdings Limited | COMPOSITION FOR PREVENTING DECREASE IN MUSCLE MASS, PREVENTING WEAKNESS IN MUSCLE STRENGTH, INCREASE MUSCLE MASS OR STRENGTHENING MUSCLE STRENGTH |
| JPWO2022131063A1 (ja) * | 2020-12-18 | 2022-06-23 | ||
| CN114958730A (zh) * | 2022-04-22 | 2022-08-30 | 南京农业大学 | 一种肌肉干细胞增殖培养基、分化培养基及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100441590C (zh) * | 2006-03-10 | 2008-12-10 | 中山大学 | 槲皮素类化合物及其糖苷的金属配合物及其应用 |
| JP2008255075A (ja) | 2007-04-09 | 2008-10-23 | Daidoo Dorinko Kk | 血管内皮機能の改善剤および健康食品 |
| JP2013126951A (ja) * | 2010-03-01 | 2013-06-27 | Kyushu Univ | 筋萎縮阻害剤 |
| JP2014015428A (ja) * | 2012-07-10 | 2014-01-30 | Kao Corp | サテライト細胞分化促進剤 |
| JP2014037387A (ja) * | 2012-08-18 | 2014-02-27 | Kobe Gakuin | 筋ジストロフィー治療剤 |
| US20170042924A1 (en) * | 2014-04-28 | 2017-02-16 | Suntory Holdings Limited | Muscle atrophy inhibitor containing quercetin glycoside |
-
2016
- 2016-04-22 US US15/568,810 patent/US20180104269A1/en not_active Abandoned
- 2016-04-22 SG SG11201708158PA patent/SG11201708158PA/en unknown
- 2016-04-22 WO PCT/JP2016/062700 patent/WO2016175136A1/ja active Application Filing
- 2016-04-22 JP JP2017515526A patent/JP7013238B2/ja active Active
- 2016-04-22 CA CA2982645A patent/CA2982645C/en active Active
- 2016-04-22 CN CN201680023112.6A patent/CN107530320A/zh active Pending
- 2016-04-22 SG SG10201909412R patent/SG10201909412RA/en unknown
- 2016-04-26 TW TW105112956A patent/TW201713330A/zh unknown
-
2018
- 2018-05-03 HK HK18105727.9A patent/HK1246182A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180104269A1 (en) | 2018-04-19 |
| TW201713330A (zh) | 2017-04-16 |
| CN107530320A (zh) | 2018-01-02 |
| CA2982645C (en) | 2024-02-13 |
| JPWO2016175136A1 (ja) | 2018-02-15 |
| HK1246182A1 (zh) | 2018-09-07 |
| WO2016175136A1 (ja) | 2016-11-03 |
| JP7013238B2 (ja) | 2022-01-31 |
| SG10201909412RA (en) | 2019-11-28 |
| CA2982645A1 (en) | 2016-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201512030D0 (en) | Composition | |
| GB201521507D0 (en) | Composition | |
| GB201505527D0 (en) | Composition | |
| HK1246182A1 (zh) | 肌肉脂肪化抑制用組合物 | |
| RS58971B1 (sr) | Kompozicija za okularno zdravlje | |
| GB201515640D0 (en) | Composition | |
| GB201506825D0 (en) | Composition | |
| GB201506830D0 (en) | Composition | |
| GB201506829D0 (en) | Composition | |
| GB201517546D0 (en) | Composition | |
| GB201522603D0 (en) | Composition | |
| GB201506828D0 (en) | Composition | |
| GB201504307D0 (en) | Composition | |
| GB201518348D0 (en) | Composition | |
| GB201515639D0 (en) | Composition | |
| GB201511697D0 (en) | Composition | |
| GB201509044D0 (en) | Composition | |
| GB201505520D0 (en) | Composition | |
| PL3347444T3 (pl) | Kompozycje tłuszczowe | |
| PL3344070T3 (pl) | Jadalna kompozycja | |
| GB201519327D0 (en) | Composition | |
| GB201508722D0 (en) | Composition | |
| GB201506826D0 (en) | Composition | |
| GB201521384D0 (en) | Composition | |
| GB201520125D0 (en) | Composition |